Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07161115 by Longhao Li, with a registry enrolment figure of 60 participants, started 2025-09-19 and due to reach its primary completion in 2028-08-31. Interventions recorded: Reduced-field short-course radiotherapy; Immunotherapy combined with chemotherapy; Standard short-course radiotherapy; Standard long-course radiotherapy; Chemotherapy. Conditions listed: Rectal Adenocarcinoma. Primary outcome: Two-year local control rate after rectal cancer surgery. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.